Drug and device manufacturers are raising concerns about President Donald Trump’s tariffs on imports from China, Mexico, and Canada, warning that they could worsen tensions in medical supply chains and lead to shortages, if their products are not exempted.
On 1 February, the White House announced the imposition of tariffs on imported goods from Mexico, Canada, and China. On 3 February, President Trump announced a 30-day pause on the tariffs for goods imported from Mexico and Canada; however, the 10% tariff on imports from China remains in effect. This action was taken to “hold Mexico, Canada, and China accountable for their promises to halt illegal immigration and stop the flow of harmful fentanyl and other drugs into our country.”
Trade groups representing the pharmaceutical and medical device sectors opposed the tariffs and are pushing for exemptions…
